195 related articles for article (PubMed ID: 17296886)
1. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis.
Pignone M; Earnshaw S; Pletcher MJ; Tice JA
Arch Intern Med; 2007 Feb; 167(3):290-5. PubMed ID: 17296886
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
Greving JP; Buskens E; Koffijberg H; Algra A
Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
[TBL] [Abstract][Full Text] [Related]
3. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
4. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
Schleinitz MD; Weiss JP; Owens DK
Am J Med; 2004 Jun; 116(12):797-806. PubMed ID: 15178495
[TBL] [Abstract][Full Text] [Related]
5. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
Logman JF; Heeg BM; Herlitz J; van Hout BA
Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
[TBL] [Abstract][Full Text] [Related]
7. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.
Pignone M; Earnshaw S; Tice JA; Pletcher MJ
Ann Intern Med; 2006 Mar; 144(5):326-36. PubMed ID: 16520473
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.
Saini SD; Schoenfeld P; Fendrick AM; Scheiman J
Arch Intern Med; 2008 Aug; 168(15):1684-90; discussion 1691. PubMed ID: 18695083
[TBL] [Abstract][Full Text] [Related]
10. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.
Greving JP; Visseren FL; de Wit GA; Algra A
BMJ; 2011 Mar; 342():d1672. PubMed ID: 21450800
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
12. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
Gaspoz JM; Coxson PG; Goldman PA; Williams LW; Kuntz KM; Hunink MG; Goldman L
N Engl J Med; 2002 Jun; 346(23):1800-6. PubMed ID: 12050341
[TBL] [Abstract][Full Text] [Related]
14. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis.
Quinn RR; Naimark DM; Oliver MJ; Bayoumi AM
Am J Kidney Dis; 2007 Sep; 50(3):421-32. PubMed ID: 17720521
[TBL] [Abstract][Full Text] [Related]
15. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
Lindgren P; Stenestrand U; Malmberg K; Jönsson B
Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
[TBL] [Abstract][Full Text] [Related]
16. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation.
Annemans L; Lamotte M; Kubin M; Evers T; Verheugt FW
Int J Clin Pract; 2006 Sep; 60(9):1129-37. PubMed ID: 16939558
[TBL] [Abstract][Full Text] [Related]
17. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
18. An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease.
Shaker M; Lobb A; Jenkins P; O'Rourke D; Takemoto SK; Sheth S; Burroughs T; Dykewicz MS
J Allergy Clin Immunol; 2008 Jan; 121(1):81-7. PubMed ID: 17716716
[TBL] [Abstract][Full Text] [Related]
19. [Health economic evaluation of low-dose acetylsalicylic acid in the primary prevention of cardiovascular disease].
Lamotte M; Piñol C; Brotons C; Annemans L; Guardiola E; Evers T; Kubin M
Rev Esp Cardiol; 2006 Aug; 59(8):807-15. PubMed ID: 16938230
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease.
Shiffman D; Slawsky K; Fusfeld L; Devlin JJ; Goss TF
Clin Ther; 2012 Jun; 34(6):1387-94. PubMed ID: 22560621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
